Company: CNTB
Filing Date: 2025-09-10
Form Type: POS AM
Source: 0001193125-25-200186
Chunk: 70

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-09-10
Form: POS AM
Chunk 70
---
, document                                                                                     
 submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements. |

| • |     | Third-party claims or litigation alleging infringement, misappropriation or other violation of, or seeking to                                                                    
 invalidate, patents or other intellectual and proprietary rights, may delay or prevent the development and commercialization of any of our current or future Product Candidates. |

| • |     | We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or                      
 expiration of a third-party patent, which might adversely affect our ability to develop and market our Product Candidates. |

| • |     | We may need to acquire or license intellectual property from third parties, and such licenses may not be 
 available or may not be available on commercially reasonable terms.                                      |

| • |     | We may become involved in lawsuits to protect or enforce our patents or other intellectual property rights, 
 which could be expensive, time-consuming and unsuccessful.                                                  |

| • |     | Derivation, interference or other proceedings may be necessary to determine priority of inventions relating to                                                                       
 our current or future Product Candidates, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party. |

| • |     | Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual 
 property rights against third parties.                                                                        |

| • |     | Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our                                                                           
 current and future patent applications or those of our future licensors and the enforcement or defense of our current and future issued patents or those of our future licensors. |

7

| • |     | Changes in U.S. patent law, PRC patent law or patent laws in other countries could diminish the value of    
 patents in general, thereby impairing our ability to protect our current and any future Product Candidates. |

| • |     | We may not be able to protect our intellectual property rights throughout the world, including in the PRC. |

| • |     | Compulsory standards for remuneration to creators or inventors of the patents they contribute to our business 
 could be considerable.                                                                                        |

| • |     | If we are unable to protect the confidentiality of our trade secrets, our business and competitive position 
 would be harmed.                                                                                            |

| • |     | We may be subject to claims that our employees, consultants or independent contractors